Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.88
AVEO's Cash to Debt is ranked lower than
68% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. AVEO: 2.88 )
Ranked among companies with meaningful Cash to Debt only.
AVEO' s Cash to Debt Range Over the Past 10 Years
Min: 1.54  Med: 5.68 Max: N/A
Current: 2.88
Equity to Asset 0.19
AVEO's Equity to Asset is ranked lower than
88% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AVEO: 0.19 )
Ranked among companies with meaningful Equity to Asset only.
AVEO' s Equity to Asset Range Over the Past 10 Years
Min: -3.21  Med: 0.48 Max: 0.79
Current: 0.19
-3.21
0.79
F-Score: 3
Z-Score: -15.16
M-Score: 9.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -59.71
AVEO's Operating margin (%) is ranked higher than
54% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. AVEO: -59.71 )
Ranked among companies with meaningful Operating margin (%) only.
AVEO' s Operating margin (%) Range Over the Past 10 Years
Min: -8035.89  Med: -211.41 Max: 20.59
Current: -59.71
-8035.89
20.59
Net-margin (%) -74.39
AVEO's Net-margin (%) is ranked higher than
52% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. AVEO: -74.39 )
Ranked among companies with meaningful Net-margin (%) only.
AVEO' s Net-margin (%) Range Over the Past 10 Years
Min: -8277.57  Med: -219.61 Max: 18.59
Current: -74.39
-8277.57
18.59
ROE (%) -106.25
AVEO's ROE (%) is ranked lower than
83% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. AVEO: -106.25 )
Ranked among companies with meaningful ROE (%) only.
AVEO' s ROE (%) Range Over the Past 10 Years
Min: -116.49  Med: -90.07 Max: 20.76
Current: -106.25
-116.49
20.76
ROA (%) -39.09
AVEO's ROA (%) is ranked lower than
60% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. AVEO: -39.09 )
Ranked among companies with meaningful ROA (%) only.
AVEO' s ROA (%) Range Over the Past 10 Years
Min: -88.25  Med: -52.18 Max: 13.74
Current: -39.09
-88.25
13.74
ROC (Joel Greenblatt) (%) -8448.25
AVEO's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. AVEO: -8448.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AVEO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8448.25  Med: -791.02 Max: 689.47
Current: -8448.25
-8448.25
689.47
Revenue Growth (3Y)(%) -55.60
AVEO's Revenue Growth (3Y)(%) is ranked lower than
87% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. AVEO: -55.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AVEO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -75.7 Max: -55.6
Current: -55.6
» AVEO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

AVEO Guru Trades in Q3 2015

Paul Tudor Jones 83,869 sh (+1.92%)
Jim Simons 2,091,800 sh (-1.37%)
» More
Q4 2015

AVEO Guru Trades in Q4 2015

Paul Tudor Jones 83,869 sh (unchged)
Jim Simons 1,975,900 sh (-5.54%)
» More
Q1 2016

AVEO Guru Trades in Q1 2016

Jim Simons 2,094,900 sh (+6.02%)
Paul Tudor Jones 83,869 sh (unchged)
» More
Q2 2016

AVEO Guru Trades in Q2 2016

Jim Simons 2,405,400 sh (+14.82%)
Paul Tudor Jones 83,869 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CHMA, OTCPK:COTQF, NAS:TENX, NAS:CATB, NAS:VCEL, NAS:KMPH, OTCPK:OGRMF, NAS:NTEC, OTCPK:MCUJF, OTCPK:IMMVF, NAS:DMPI, OTCPK:CWBR, NAS:BLRX, OTCPK:BIOAF, NAS:INFI, NAS:SNSS, NAS:MBRX, NAS:AVIR, NAS:PIRS, OTCPK:AMEUF » details
Traded in other countries:VPA.Germany,
AVEO Pharmaceuticals Inc is a biopharmaceutical company. It is involved in discovering, developing and commercializing novel cancer therapeutics.

AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The Company's proprietary Human Response Platform provides the company insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.

Ratios

vs
industry
vs
history
P/B 8.17
AVEO's P/B is ranked lower than
78% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. AVEO: 8.17 )
Ranked among companies with meaningful P/B only.
AVEO' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 2.97 Max: 22.25
Current: 8.17
0.87
22.25
P/S 2.51
AVEO's P/S is ranked higher than
83% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. AVEO: 2.51 )
Ranked among companies with meaningful P/S only.
AVEO' s P/S Range Over the Past 10 Years
Min: 0.63  Med: 4.06 Max: 101.25
Current: 2.51
0.63
101.25
Current Ratio 6.07
AVEO's Current Ratio is ranked higher than
59% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. AVEO: 6.07 )
Ranked among companies with meaningful Current Ratio only.
AVEO' s Current Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.46 Max: 9.47
Current: 6.07
1.47
9.47
Quick Ratio 6.07
AVEO's Quick Ratio is ranked higher than
61% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. AVEO: 6.07 )
Ranked among companies with meaningful Quick Ratio only.
AVEO' s Quick Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.46 Max: 9.47
Current: 6.07
1.47
9.47
Days Sales Outstanding 23.58
AVEO's Days Sales Outstanding is ranked higher than
80% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. AVEO: 23.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVEO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.19  Med: 29.59 Max: 390.8
Current: 23.58
3.19
390.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.50
AVEO's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. AVEO: -6.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVEO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.9  Med: -6.5 Max: 0
Current: -6.5
-13.9
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.71
AVEO's Price/Net Cash is ranked lower than
71% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. AVEO: 12.71 )
Ranked among companies with meaningful Price/Net Cash only.
AVEO' s Price/Net Cash Range Over the Past 10 Years
Min: 1.75  Med: 4.93 Max: 24.76
Current: 12.71
1.75
24.76
Price/Net Current Asset Value 8.90
AVEO's Price/Net Current Asset Value is ranked lower than
64% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. AVEO: 8.90 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AVEO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.42  Med: 3.53 Max: 19.54
Current: 8.9
1.42
19.54
Price/Tangible Book 8.09
AVEO's Price/Tangible Book is ranked lower than
70% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. AVEO: 8.09 )
Ranked among companies with meaningful Price/Tangible Book only.
AVEO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.2  Med: 3.11 Max: 14.72
Current: 8.09
1.2
14.72
Price/Median PS Value 0.62
AVEO's Price/Median PS Value is ranked higher than
75% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. AVEO: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
AVEO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 1.14 Max: 23.13
Current: 0.62
0.18
23.13
Earnings Yield (Greenblatt) (%) -28.82
AVEO's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. AVEO: -28.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AVEO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -28.82  Med: 164.4 Max: 47812.4
Current: -28.82
-28.82
47812.4

More Statistics

Revenue (TTM) (Mil) $20.15
EPS (TTM) $ -0.24
Beta1.27
Short Percentage of Float2.24%
52-Week Range $0.81 - 1.47
Shares Outstanding (Mil)75.86
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Other Websites
AVEO Pharmaceuticals (AVEO) Sees Hammer Chart Pattern: Time to Buy? Sep 26 2016
AVEO Collaborates With Bristol-Myers Squibb for RCC Drug (AVEO, BMY) Sep 22 2016
5 Biotech Stocks That Are Broker Favorites Sep 13 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Other Events Sep 12 2016
ETF’s with exposure to AVEO Pharmaceuticals, Inc. : September 9, 2016 Sep 09 2016
AVEO to Present at the 18th Annual Rodman & Renshaw Global Investment Conference Sep 06 2016
The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen Aug 18 2016
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data Aug 17 2016
Bristol-Myers Squibb (BMY) Stock Falls, Bernstein: Failed Trial Impact to Persist Aug 15 2016
AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo®... Aug 15 2016
AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo®... Aug 15 2016
AVEO PHARMACEUTICALS INC Financials Aug 13 2016
ETF’s with exposure to AVEO Pharmaceuticals, Inc. : August 11, 2016 Aug 11 2016
AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 Aug 09 2016
AVEO (AVEO) Reports a Wider Loss in Q2, Tivozanib in Focus Aug 05 2016
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q2 Aug 04 2016
AVEO reports 2Q loss Aug 04 2016
AVEO reports 2Q loss Aug 04 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2016
AVEO Oncology Reports Second Quarter 2016 Financial Results and Provides Business Update Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)